Next generation hybrid nanomaterials: bispecific antibody-targeted polymers

下一代混合纳米材料：双特异性抗体靶向聚合物

• 批准号: LP150100703
• 负责人: Prof Kristofer Thurecht
• 金额: $ 25.03万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-06-29 至 2019-06-28
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP150100703
• 关键词: Next; generation; hybrid; nanomaterials; bispecific

This project aims to develop and optimise a novel platform technology that will assist in the development of hybrid materials consisting of nanomaterials and biomolecules, which form the basis of many commercial diagnostic devices. A novel antibody, MIL38, will provide the test bed for the technology, which will aim to deliver a platform that is stable under physiological conditions and that enables facile conjugation of nanomaterials with antibodies. This project has the potential to rapidly improve the ligation process between synthetic nanomaterials and biologics, leading to more efficient synthesis of targeted diagnostics. This would provide a significant commercial advantage for any nanomaterials developed for the field, and specifically for this project, expedite translation of MIL38.

该项目旨在开发和优化一种新的平台技术，该技术将有助于由纳米材料和生物分子组成的混合材料的开发，这些材料构成了许多商业诊断设备的基础。一种名为MIL38的新型抗体将为这项技术提供试验台，该技术旨在提供一个在生理条件下稳定的平台，并使纳米材料能够轻松地与抗体偶联。该项目有可能迅速改进合成纳米材料和生物制品之间的连接过程，导致更有效地合成靶向诊断。这将为为该领域开发的任何纳米材料提供显著的商业优势，特别是为这个项目，加快MIL38的翻译。